Oncology
Squamous Cell Lung Carcinoma
20
Pipeline Programs↗
0
Active Trials↗
14
Companies Involved↗
Squamous Cell Lung Carcinoma is an emerging landscape with 20 programs across 14 companies. The most active players are AstraZeneca, Summit Therapeutics, Innovent Biologics (Suzhou) Co. Ltd.. 6 therapies are approved with 3 more in late-stage development.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical
No programs
Phase 1
No programs
Phase 211
Phase 33
Analysis
Modality Breakdown
22programs
Small molecule1255%
Monoclonal antibody1045%
Modality classified for 100% of 22 pipeline programs.
Analysis
Trial Status
3
clinical trials
Unknown status1 · 33%
Completed1 · 33%
Withdrawn1 · 33%
Clinical Trials
Trial Activity
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)